Q1 26 EPS
$-0.56
Q1 26 Revenue
$246.0M
BEAT +25.50%
Est. $196.0M
vs S&P Since Q1 26
+3.3%
BEATING MARKET
IONS +4.6% vs S&P +1.3%
Market Reaction
Did IONS Beat Earnings? Q1 2026 Results
Ionis Pharmaceuticals delivered a strong first-quarter 2026 beat on both the top and bottom lines, with revenue of $246.00 million coming in 25.50% ahead of the $196.01 million consensus and rising 86.9% from the year-ago period, while a GAAP loss of… Read more Ionis Pharmaceuticals delivered a strong first-quarter 2026 beat on both the top and bottom lines, with revenue of $246.00 million coming in 25.50% ahead of the $196.01 million consensus and rising 86.9% from the year-ago period, while a GAAP loss of $0.56 per share beat the $0.78 consensus estimate by 27.74%. The primary engine behind the outperformance was an surge in R&D revenue to $138.00 million, fueled by roughly $95.00 million in clinical and regulatory milestone payments from partner agreements, complemented by 42% growth in commercial revenue to $108.00 million as newer products TRYNGOLZA and DAWNZERA gained traction. Management responded to the momentum by raising full-year 2026 total revenue guidance to $875.00 million to $900.00 million and boosting peak net sales expectations for olezarsen in severe hypertriglyceridemia to more than $3.00 billion, while the company keeps its sights on cash-flow breakeven by 2028 amid a busy regulatory calendar that includes three PDUFA dates and major cardiovascular outcomes trial readouts later this year.
Key Takeaways
- • 87% year-over-year revenue growth driven by commercial success and substantial R&D milestone payments
- • TRYNGOLZA showing increasing demand in FCS driven by strong launch execution
- • DAWNZERA sales increased 125% sequentially versus Q4 2025
- • Approximately $95 million in clinical and regulatory milestone payments from multiple partnerships
- • Commercial revenue increased 42% year-over-year to $108 million
IONS Forward Guidance & Outlook
Ionis raised its full-year 2026 financial guidance: total revenue now expected at $875–$900 million (up from $800–$825 million), non-GAAP operating loss narrowed to $425–$475 million (from $500–$550 million), TRYNGOLZA full-year product sales guided at $100–$110 million, DAWNZERA full-year product sales guided at $110–$120 million, and cash/short-term investments expected to remain above $1.6 billion. The company increased peak net sales guidance for olezarsen in sHTG to >$3 billion from >$2 billion. Ionis reiterated its goal of reaching cash-flow breakeven in 2028. Key upcoming catalysts include PDUFA dates for olezarsen in sHTG (June 30, 2026), zilganersen for Alexander disease (September 22, 2026), and bepirovirsen for chronic hepatitis B (October 26, 2026), as well as Phase 3 outcomes data for pelacarsen (Lp(a) HORIZON) and eplontersen (CARDIO-TTRansform) cardiovascular outcomes trials later in 2026.
IONS YoY Financials
Q1 2026 vs Q1 2025, source: SEC Filings
IONS Revenue by Segment
With YoY comparisons, source: SEC Filings
“Ionis' strong performance in the first quarter of 2026 underscores the strength of our commercial and R&D engines. Our independent launches are increasingly contributing to revenue, driven by strong commercial execution, and we are on track for two additional groundbreaking independent launches in 2026 — olezarsen for severe hypertriglyceridemia, our first medicine for a broad patient population, and zilganersen for Alexander disease, the first launch from our leading neurology pipeline.”
— Brett P. Monia, Q1 2026 Earnings Press Release
IONS Earnings Trends
IONS vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
IONS EPS Trend
Earnings per share: estimate vs actual
IONS Revenue Trend
Quarterly revenue: estimate vs actual
IONS Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $-0.56 | — | $246.0M | +25.50% |
| Q4 25 MISS FY | $-1.33 | $-1.41 | -6.02% | $203.0M | +29.23% |
| FY Full Year | $-1.66 | $-2.38 | -42.96% | $944.0M | +5.18% |
| Q3 25 BEAT | $-1.05 | $-0.80 | +23.99% | $157.0M | +20.30% |
| Q2 25 BEAT | $0.16 | $0.70 | +326.05% | $452.0M | +51.18% |
| Q1 25 BEAT | $-1.03 | $-0.93 | +9.86% | $132.0M | +7.75% |